These studies unraveled the specific roles of AKT isoforms in stemness, invasions and therapeutic response of cisplatin in TNBCs, therefore suggesting that it is imperative to precisely design isoform-specific inhibitors in the treatment of aggressive triple-negative breast cancers. Here, AKT1 is linked to triple-negative breast carcinoma.